Abstract
Background
Fibrotic focus (FF) has been observed in breast cancers and is suggested to be an important prognostic marker. However, most of these observations were reported by the same group of investigators with similar sample cohort. The relationship of FF and molecular subtypes as well as its associated prognosis has not been elucidated.
Methods
In this study, 450 cases of breast carcinomas were evaluated for the presence of FF and its association with clinicopathologic parameters and biomarkers.
Results
FF was found in 18.7 % of all consecutive cases. FF was associated positively with infiltrative margins (p = 0.03) but negatively with extensive in situ component (p < 0.001) and lymphocytic infiltration (p < 0.001). It was positively associated with estrogen receptor (p = 0.007) but negatively with human epidermal growth factor receptor 2 (HER2; p = 0.001), epidermal growth factor receptor (p = 0.021), Ki-67 (p = 0.001), and c-kit (p = 0.009). Concomitantly, FF was seen more commonly in luminal A cancers (p < 0.001) but less so in luminal B (p = 0.045) and HER2-overexpressing cancers (p = 0.011). Analysis on patient outcome (median 41 months, range 1–69 months) indicated that FF was an independent poor prognostic factor for disease-free survival (hazard ratio = 2.57; 95 % confidence interval = 1.267–5.214, p = 0.009), particularly in the luminal B subtype.
Conclusions
The findings suggested that FF is associated with specific tumor morphology of an infiltrative, stellate pattern (typical invasive ductal carcinoma-not otherwise specified) rather than round, cellular mass with intense lymphocytic infiltrate (basal-like breast cancers). The poor prognostic implication of FF is additional and independent of other adverse prognostic indicators.
Similar content being viewed by others
References
Fisher ER, Palekar AS, Sass R, Fisher B. Scar cancers: pathologic findings from the national surgical adjuvant breast project (protocol no. 4): IX. Breast Cancer Res Treat. 1983;3(1):39–59.
Hasebe T, Mukai K, Tsuda H, Ochiai A. New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int. 2000;50(4):263–72.
Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res. 1996;87(4):385–94.
Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15(5):502–16.
Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49(3):195–208.
Hasebe T, Tsuda H, Tsubono Y, Imoto S, Mukai K. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within 3 years after the initial operation. Jpn J Cancer Res. 1997;88(6):590–9.
Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ, eds. World health organization classification of tumors of the breast. 4th ed. Lyon: IARC Press; 2012.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.
Van den Eynden GG, Colpaert CG, Couvelard A, et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology. 2007;51(4):440–51.
Tsang JY, Lai MW, Wong KH, et al. alphaB-crystallin is a useful marker for triple negative and basal breast cancers. Histopathology. 2012; 61(3):378–86.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.
Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.
Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18(1):26–35.
Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol. 2010;23(10):1357–63.
Leonardi E, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992;45(5):416–9.
Acknowledgment
All authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mujtaba, S.S., Ni, YB., Tsang, J.Y.S. et al. Fibrotic Focus in Breast Carcinomas: Relationship with Prognostic Parameters and Biomarkers. Ann Surg Oncol 20, 2842–2849 (2013). https://doi.org/10.1245/s10434-013-2955-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-013-2955-0